Human Molecular Genetics, 2001, Vol. 10, No. 7 669-675
© 2001 Oxford University Press
Unraveling human cancer in the mouse: recent refinements to modeling and analysis
Departments of Pediatrics and Medicine, UCSD Cancer Center, UCSD School of Medicine, 9500 Gilman Drive, Mail Code 0627, La Jolla, CA 92093, USA
The ability to manipulate the mouse genome has made the mouse the primary mammalian genetic model organism. It has been possible to model human cancer in the mouse by overexpressing oncogenes or inactivating tumor suppressor genes, and these experiments have provided much of our in vivo understanding of cancer. However, these transgenic approaches do not always completely and accurately model human carcinogenesis. Recent developments in transgenic and knockout approaches have improved the accuracy of modeling somatic cancer in the mouse and analyzing the genomic instability that occurs in murine tumors. It is possible to use retroviral gene delivery, chromosome engineering and inducible transgenes to selectively manipulate the genome in a more precise spatial and temporal pattern. In addition, the development of powerful cytogenetic tools such as spectral karyotyping, fluorescence in situ hybridization and comparative genome hybridization have improved our ability to detect chromosomal rearrangements. Finally, global patterns of gene expression can be determined by microarray analysis to decipher complex gene patterns which occur in cancers. Several of these advances in mouse modeling of human cancer are discussed in this review.
+ These authors contributed equally to this work
§ To whom correspondence should be addressed. Tel: +1 858 822 3400; Fax: +1 858 822 3409; Email: awynshawboris@ucsd.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Suzuki, H. Kohno, M. Suzui, N. Yoshimi, H. Tsuda, K. Wakabayashi, and T. Tanaka An animal model for the rapid induction of tongue neoplasms in human c-Ha-ras proto-oncogene transgenic rats by 4-nitroquinoline 1-oxide: its potential use for preclinical chemoprevention studies Carcinogenesis, March 1, 2006; 27(3): 619 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Suggitt and M. C. Bibby 50 Years of Preclinical Anticancer Drug Screening: Empirical to Target-Driven Approaches Clin. Cancer Res., February 1, 2005; 11(3): 971 - 981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C.L. Schuh Trials, Tribulations, and Trends in Tumor Modeling in Mice Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Edinger, Y.-A. Cao, M. R. Verneris, M. H. Bachmann, C. H. Contag, and R. S. Negrin Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging Blood, January 15, 2003; 101(2): 640 - 648. [Abstract] [Full Text] [PDF]
|
|